Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: Results of a phase I/II study

Authors

Carrie L Kitko, Vanderbilt University
Iskra Pusic, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

4-1-2023

Volume

41

Issue

10

First Page

1864

Last Page

1875

Document Type

Open Access Publication

DOI

10.1200/JCO.22.00958

Rights and Permissions

Kitko CL, Arora M, DeFilipp Z, Zaid MA, Di Stasi A, Radojcic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, Lee SJ. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2023 Apr 1;41(10):1864-1875. doi: 10.1200/JCO.22.00958. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Kitko, Carrie L; Pusic, Iskra; and et al., "Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: Results of a phase I/II study." Journal of Clinical Oncology. 41, 10. 1864 - 1875. (2023).
https://digitalcommons.wustl.edu/oa_4/1642

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.